BusinessBusiness & EconomyBusiness Line

Promise of Eli Lilly’s weight-loss drug for sleep apnea provides yet every other motive to possess the stock

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York Metropolis on Dec. 11, 2023.

Brendan Mcdermid | Reuters

Eli Lilly‘s weight-loss drug Zepbound showed promise as a medication for sleep apnea — giving investors more confidence to take care of proudly owning the realm’s most necessary properly being-care company even after or no longer it has been crushing the S&P 500’s efficiency all by scheme of the last three years.

Content Protection by

Back to top button